SPRY
ARS Pharmaceuticals, Inc.
Biotechnology
Market Cap$894M
5Y Perf.-81.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SPRY vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.-60.0%
SPRY vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SPRY | PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $894M | $9.63B |
| Revenue (TTM) | $84M | $-92K |
| Net Income (TTM) | $-171M | $-327M |
| Gross Margin | 54.4% | — |
| Operating Margin | -212.9% | — |
| Total Debt | $0.00 | $110K |
| Cash & Equiv. | $41M | $357M |
SPRY vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SPRY
PRAX
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| ARS Pharmaceuticals… (SPRY) | 100 | 18.9 | -81.1% |
| Praxis Precision Me… (PRAX) | 100 | 40.0 | -60.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SPRY vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRAX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. ARS Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SPRY
ARS Pharmaceuticals, Inc.
The Income Pick
SPRY is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.47
- Rev growth -5.5%, EPS growth -23.3%, 3Y rev CAGR 300.1%
- Lower volatility, beta 1.47, current ratio 7.28x
Best for: income & stability and growth exposure
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder
PRAX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -20.1% 10Y total return vs SPRY's -64.0%
- 2.4% margin vs SPRY's -203.3%
- +7.7% vs SPRY's -33.3%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SPRY | -5.5% revenue growth vs PRAX's -100.0% |
| Quality / Margins | PRAX | 2.4% margin vs SPRY's -203.3% |
| Stability / Safety | SPRY | Beta 1.47 vs PRAX's 1.55 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs SPRY's -33.3% |
| Efficiency (ROA) | PRAX | -40.2% ROA vs SPRY's -51.1%, ROIC -65.0% vs -96.5% |
SPRY vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
SPRY vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGSPRY
SPRYARS Pharmaceuticals, …
0leads
PRAXPraxis Precision Medi…
4leads
6 Total Categories
CATEGORYLEADERvs SPRYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRAX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX6/6
Risk & VolatilityBeta, volatility, and downside exposure
PRAX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRAX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SPRY and PRAX operate at a comparable scale, with $84M and -$92,000 in trailing revenue.
| Metric | SPRYARS Pharmaceutica… | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $84M | -$92,000 |
| EBITDAEarnings before interest/tax | -$178M | -$357M |
| Net IncomeAfter-tax profit | -$171M | -$327M |
| Free Cash FlowCash after capex | -$171M | -$283M |
| Gross MarginGross profit ÷ Revenue | +54.4% | — |
| Operating MarginEBIT ÷ Revenue | -2.1% | — |
| Net MarginNet income ÷ Revenue | -2.0% | — |
| FCF MarginFCF ÷ Revenue | -2.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -67.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -180.4% | +2.7% |
PRAX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SPRY and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SPRYARS Pharmaceutica… | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $894M | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $852M | $9.3B |
| Trailing P/EPrice ÷ TTM EPS | -5.17x | -24.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 10.60x | — |
| Price / BookPrice ÷ Book value/share | 7.76x | 8.54x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SPRY and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-100 for SPRY.
| Metric | SPRYARS Pharmaceutica… | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -100.3% | -43.0% |
| ROA (TTM)Return on assets | -51.1% | -40.2% |
| ROICReturn on invested capital | -96.5% | -65.0% |
| ROCEReturn on capital employed | -58.2% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$41M | -$357M |
| Cash & Equiv.Liquid assets | $41M | $357M |
| Total DebtShort + long-term debt | $0 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
PRAX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $7,918 today (with dividends reinvested), compared to $3,196 for SPRY. Over the past 12 months, PRAX leads with a +775.0% total return vs SPRY's -33.3%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs SPRY's 14.4% — a key indicator of consistent wealth creation.
| Metric | SPRYARS Pharmaceutica… | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | -21.7% | +16.4% |
| 1-Year ReturnPast 12 months | -33.3% | +775.0% |
| 3-Year ReturnCumulative with dividends | +49.8% | +1976.5% |
| 5-Year ReturnCumulative with dividends | -68.0% | -20.8% |
| 10-Year ReturnCumulative with dividends | -64.0% | -20.1% |
| CAGR (3Y)Annualised 3-year return | +14.4% | +174.9% |
PRAX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
PRAX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SPRY is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs SPRY's 47.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SPRYARS Pharmaceutica… | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 1.40x |
| 52-Week HighHighest price in past year | $18.90 | $356.00 |
| 52-Week LowLowest price in past year | $6.66 | $35.18 |
| % of 52W HighCurrent price vs 52-week peak | +47.6% | +93.6% |
| RSI (14)Momentum oscillator 0–100 | 66.1 | 55.6 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 378K |
PRAX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SPRY as "Hold" and PRAX as "Buy". Consensus price targets imply 183.3% upside for SPRY (target: $26) vs 64.7% for PRAX (target: $549).
| Metric | SPRYARS Pharmaceutica… | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $25.50 | $548.80 |
| # AnalystsCovering analysts | 10 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 4 of 6 categories
Loading custom metrics...
SPRY vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SPRY or PRAX a better buy right now?
For growth investors, ARS Pharmaceuticals, Inc.
(SPRY) is the stronger pick with -5. 5% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SPRY or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -20. 8%, compared to -68. 0% for ARS Pharmaceuticals, Inc. (SPRY). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus SPRY's -65. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SPRY or PRAX?
By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.
(PRAX) is the lower-risk stock at 1. 40β versus ARS Pharmaceuticals, Inc. 's 1. 47β — meaning SPRY is approximately 5% more volatile than PRAX relative to the S&P 500.
04Which is growing faster — SPRY or PRAX?
By revenue growth (latest reported year), ARS Pharmaceuticals, Inc.
(SPRY) is pulling ahead at -5. 5% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Praxis Precision Medicines, Inc. grew EPS -32. 0% year-over-year, compared to -23. 3% for ARS Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SPRY or PRAX?
Praxis Precision Medicines, Inc.
(PRAX) is the more profitable company, earning 0. 0% net margin versus -203. 3% for ARS Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRAX leads at 0. 0% versus -212. 9% for SPRY. At the gross margin level — before operating expenses — SPRY leads at 54. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SPRY or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SPRY or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Praxis Precision Medicines, Inc.
(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (PRAX: -20. 9%, SPRY: -65. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SPRY and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SPRY: -67.6% · PRAX: -100.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.